Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immunovia ABIMMVF -61.59%41 Earnings per Share (Diluted) is $-0.02 as of Jun. 2026. GuruFocus rates IMMVF with a GF Score™ of 41/100 and a GF Value™ of $0.02. The stock has 6 warning signs investors should review. Among 158 Medical Diagnostics & Research companies, Immunovia AB ranks better than 82.28% on this metric.
Immunovia AB's EPS (Basic) for the
three
months ended in Jun. 2026 was $-0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.02.
Immunovia AB's EPS without NRI for the
three
months ended in Jun. 2026 was $-0.00.
Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.02.
During the past 3 years, the average EPS without NRIGrowth Rate was 46.00% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 26.80% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was -13.10% per year.
During the past 13 years, Immunovia AB's highest 3-Year average EPS without NRI Growth Rate was 46.00% per year. The lowest was -93.00% per year. And the median was -36.45% per year.
Immunovia AB (OTCPK:IMMVF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Immunovia AB Earnings per Share (Diluted) Related Terms
Immunovia AB Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Immunovia AB's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMMVF vs TMO, DHR, IDXX: Earnings per Share (Diluted) Comparison
For the Diagnostics & Research subindustry, Immunovia AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovia AB PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's PE Ratio distribution charts can be found below:
* The bar in red indicates where Immunovia AB's PE Ratio falls into.
Immunovia AB Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Immunovia AB's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.02 mean?
Immunovia AB (IMMVF) has a Earnings per Share (Diluted) of $-0.02 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Immunovia AB and its competitors. According to the industry distribution chart, Immunovia AB ranks #28 out of 158 companies in the Medical Diagnostics & Research industry, placing it in the top 17.7%.
Is Immunovia AB's Earnings per Share (Diluted) too high?
Immunovia AB's current Earnings per Share (Diluted) is $-0.02. Based on the distribution chart, Immunovia AB ranks #28 out of 158 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Immunovia AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Earnings per Share (Diluted) compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Immunovia AB ranks #28 out of 158 companies for Earnings per Share (Diluted). This places Immunovia AB in the top 18% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 10.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Diagnostics & Research company?
The median Earnings per Share (Diluted) among Medical Diagnostics & Research companies is 10.75, based on 158 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Immunovia AB and its competitors. For the Medical Diagnostics & Research industry, the median Earnings per Share (Diluted) is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovia AB's current Earnings per Share (Diluted) is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current Earnings per Share (Diluted) of $-0.02. The stock's GF Value™ is $0.02, compared to a current price of $0.02 — trading right at its estimated fair value. The current Earnings per Share (Diluted) is $-0.02. Immunovia AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current Earnings per Share (Diluted) is $-0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunovia AB (IMMVF) Overvalued in 2026?
Based on GuruFocus' analysis, Immunovia AB stock appears to be undervalued.
The current stock price of $0.02 is trading 0% below its estimated GF Value™ of $0.02.
Key valuation signals for IMMVF:
Earnings per Share (Diluted): $-0.02
GF Value™: $0.02 vs. price of $0.02 (0% below fair value)
No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
41GF Score
Get the complete analysis for IMMVF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMVF has been successfully added to your 
